Navigation Links
Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Date:11/4/2008

CALGARY, Nov. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and nine-month periods ended September 30, 2008.

Recent Pivotal Trial Decision

Oncolytics made a decision in early November to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in refractory patients with head and neck cancers. The decision was made following a review of results by the Company's Board of Directors from the Company's ongoing U.K. Phase I and Phase II combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials. The results were presented November 1, 2008 at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting in San Diego, CA.

Selected Third Quarter Highlights:

- Treatment of the 200th patient in clinical studies with REOLYSIN(R);

- Completion of patient enrolment in the dose escalation portion of its

U.K. clinical trial to evaluate the anti-tumour effects of systemic

administration of REOLYSIN(R) in combination with docetaxel

(Taxotere(R)) in patients with advanced cancers including bladder,

prostate, lung and upper gastro-intestinal;

- The U.S. National Cancer Institute (NCI), part of the National

Institutes of Health, started enrolment in a Phase II clinical trial

for patients with metastatic melanoma using systemic administration

of REOLYSIN(R);

- The start of patient enrolment in a U.S. Phase II clinical trial

using intravenous administration of REOLYSIN(R) in combination with

paclitaxel and carboplatin in patients with advanced head and neck

cancers;

- Initiation of a U.S. Phase II clinical trial using intravenous

administration of REOLYSIN(R) in combination with paclitaxel and

carb
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
(Date:10/18/2014)... The “Human Insulin Market- by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/18/2014)... 18, 2014 The Asia-Pacific hardware encryption ... in Asia-Pacific with analysis and forecast of revenue. This ... expected to reach $51,362.6 million by 2018, at a ... through the TOC of the Asia-Pacific hardware encryption market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/18/2014)... According to a new market research ... - Global Trends & Forecasts up till 2017”, hydraulic ... 2011. This value is expected to increase from $40 ... 10% CAGR during the same period. North America is ... in terms of hydraulic horse power supplied by the ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4
... More Effective Than rituximab ... in a Pre-Clinical ... announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing complement ... a pre-clinical study. The CD20,antibodies were incubated with tumor cells ...
... YORK, Sept. 6 Globally, approximately 418 million,people ... danger, and costs of hepatitis in the 21st ... Hepatitis Strategies, a,new report by Kalorama Information. ... not,taking the necessary steps to contain hepatitis. Yet ...
... Globally, approximately 418 billion,people are currently infected with ... hepatitis in the 21st century cannot be,understated or ... by Kalorama Information. Paradoxically, despite the obvious ... to contain hepatitis. Yet the incidence and,prevalence of ...
Cached Biology Technology:Genmab Announces Encouraging Preclinical Data for ofatumumab 2Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health 2Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... UC San Diego have been honored by organizations for ... oceans. Postdoctoral researcher Octavio Aburto-Oropeza in Scripps, Marine ... and Conservation (CMBC) was selected to receive a Kathryn ... selected as the sole winner in a worldwide, merit-based ...
... -- The most robust statistical examination to date of our ... of all living humans -- confirms that she lived about ... a side-by-side comparison of 10 human genetic models that each ... set of assumptions about the way humans migrated, expanded and ...
... Philadelphia, PA, 17 August 2010 - Everyone is special ... view, no two humans are genetically identical. This means that ... less comm. on in the overall population. Some ... ,code, are missing entirely. These variants are likely to have ...
Cached Biology News:Scripps Oceanography biologists awarded prestigious honors 2Mother of all humans lived 200,000 years ago 2Mother of all humans lived 200,000 years ago 3Developmental problems: Some exist in the genes 2
...
...
...
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids ... Purification immunoaffinity purified Quality ... RIPA lysates from HeLa cells. ...
Biology Products: